title: Risks for fetal abnormalities after very and moderately elevated AF-AFPs.
abstract: In the 2 years between 1993 and 1995, we assayed alpha-fetoprotein (AFP) in 48,412 amniotic fluids (AFs). One thousand and eighty-six (2.2 per cent) measured > or = 2.0 MOM and these were subdivided into three groups; mildly (2.0-4.9 MOM), moderately (5.0-9.9 MOM), and very elevated (> or = 10.0 MOM). Abnormalities occurred in 25 per cent of the mildly elevated compared with 88 per cent of the moderately and 98 per cent of the very elevated cases. Forty-five per cent of the neural tube defects (NTDs) had AF-AFPs in the 5.0-9.9 and 36 per cent in the > or = 10.0 MOM range. After a positive acetylcholinesterase (AChE) test, both the moderately and the very elevated groups had abnormalities in > or = 95 per cent of cases, compared with 85 per cent in the mildly elevated group. After a negative AChE test, abnormalities occurred in 79, 52 and 18 per cent in the very elevated, moderately, and mildly elevated groups, respectively. Excluding chromosome abnormalities, an abnormal twin, and bloody samples, the risk of a fetal abnormality after a normal ultrasound was less than 1 per cent if the AChE was positive in both the moderately and the very elevated groups. If the AChE was negative, the risk was 18 per cent for the moderately and 55 per cent for the very elevated groups, of which congenital nephrosis accounted for 75 per cent; AFP levels usually increased in a later AF sample. Repeat amniocentesis may be offered to women with AF-AFPs > or = 5.0 MOM if no abnormality is seen with high-resolution ultrasound.
authors.affiliation: Department of Psychiatry, University of California, Los Angeles School of Medicine, USA.
authors.forename: B F
authors.initials: BF
authors.lastname: Crandall
authors.forename: C
authors.initials: C
authors.lastname: Chua
mesh_terms: D000110:Acetylcholinesterase / Q000032:analysis / Q000378:metabolism; D000653:Amniotic Fluid / Q000737:chemistry* / Q000378:metabolism; D002869:Chromosome Aberrations / Q000175:diagnosis / Q000453:epidemiology; D025063:Chromosome Disorders; D000013:Congenital Abnormalities / Q000175:diagnosis / Q000453:epidemiology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005189:False Positive Reactions; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis / Q000453:epidemiology*; D006801:Humans; D009436:Neural Tube Defects / Q000175:diagnosis / Q000453:epidemiology; D011247:Pregnancy / Q000378:metabolism*; D011256:Pregnancy Outcome; D011296:Prenatal Diagnosis / Q000379:methods*; D012307:Risk Factors; D013223:Statistics as Topic; D016216:Ultrasonography, Prenatal / Q000379:methods; D000509:alpha-Fetoproteins / Q000032:analysis* / Q000378:metabolism
chemical_list: D000509:alpha-Fetoproteins; D000110:Acetylcholinesterase